• Triacetin Workflows for GBM and Metabolic Research

  2026-08-19

  Triacetin, also called glyceryl triacetate, supports distinct workflows in glioblastoma apoptosis assays, hepatic metabolism studies, and ocular formulation screening. This guide converts reported concentration ranges and digestion findings into practical preparation, controls, optimization, and troubleshooting decisions.

• Puromycin dihydrochloride: Practical Lab Workflow

  2026-08-19

  Puromycin dihydrochloride is an aminonucleoside antibiotic used to select pac-expressing cells and to inhibit protein synthesis in controlled translation experiments. It should be optimized by cell type and assay endpoint, and it should not be treated as a universal selection reagent for cells that lack functional puromycin N-acetyltransferase.

• RITA (NSC 652287) Cancer Research Workflows

  2026-08-18

  RITA (NSC 652287) provides a practical way to connect MDM2-p53 pathway activation with time-resolved measurements of growth inhibition, cell death, and DNA cross-linking. This workflow-focused guide helps researchers distinguish cytostatic responses from true cytotoxicity in renal carcinoma research, apoptosis assays, and tumor xenograft model planning.

• TMRE Assay: Mapping Mitochondrial Energy Failure

  2026-08-18

  A translational framework for using TMRE fluorescence to connect sodium-driven mitochondrial dysfunction with ΔΨm loss, apoptosis research, and reproducible mitochondrial function analysis.

• Ionomycin Free Acid for Calcium-FAK Research

  2026-08-17

  Ionomycin free acid provides a controllable calcium ionophore pulse for connecting intracellular calcium dynamics with FAK stability, adhesion, and TNBC phenotypes. This workflow separates direct calcium effects from FAISL-dependent regulation and adapts the same reagent logic to oocyte activation studies without overstating the evidence.

• TH287: A Temporal Framework for MTH1 Research

  2026-08-17

  TH287 is a potent MTH1 inhibitor for investigating oxidative stress-induced DNA damage and cancer cell selective cytotoxicity. This article focuses on the underappreciated role of treatment timing, assay design, and evidence interpretation in TH287-based radiosensitization studies.

• Vernakalant for Recent-onset Atrial Fibrillation

  2026-08-16

  This post hoc analysis of ACT I and ACT IV evaluated vernakalant for rapid cardioversion of recent-onset atrial fibrillation in emergency and cardiac-care settings. The study found that intravenous treatment converted substantially more patients to sinus rhythm than placebo, with a median conversion time of 12 minutes and no observed torsade de pointes or ventricular fibrillation.

• Potassium Iodide in Translational Assay Workflows

  2026-08-15

  Potassium Iodide (KI) supports controlled studies of iodide availability, thyroid hormone synthesis, and radioactive iodine thyroid blocking. This guide turns the reagent into a practical research workflow while showing how the cascade-targeting logic of an MMP-2-responsive liposome study can inform assay design without overstating KI’s role in cancer immunotherapy.

• JHU-083: Glutaminase Workflows for Neuro Research

  2026-08-14

  JHU-083 provides a practical pharmacological entry point for testing glutaminase activity in cerebral CD11b cells, glutamate biology, and experimental cerebral malaria research. This workflow also shows how redox-focused assays from acute hepatotoxicity research can strengthen, but not replace, mechanistic validation in neurological disease models.

• SNS-032: From CDK Biology to Translational Strategy

  2026-08-14

  SNS-032 (BMS-387032) offers a mechanistically rich way to study CDK2, CDK7, and CDK9 convergence across cell-cycle regulation, transcriptional control, oncology, and host–pathogen biology. This thought-leadership perspective connects phosphorylation biomarkers, assay design, translational positioning, and the emerging relevance of CDK9-linked vesicular transport while clearly separating established evidence from testable hypotheses.

• FXR–KLF11 Signaling in Contrast-Induced AKI

  2026-08-13

  This study identifies an FXR–KLF11 transcriptional axis that protects against contrast-induced acute kidney injury by restraining JAK2/STAT3 signaling. Through mouse, HK-2 cell, transcriptomic, reporter, ChIP, and loss-of-function experiments, the authors connect nuclear-receptor activation with reduced tubular inflammation and apoptosis.

• IEM-1925 in Soman-Induced Status Epilepticus

  2026-08-13

  The 2026 NeuroToxicology study evaluates IEM-1925 in a rat model of soman-induced status epilepticus and identifies combined antiseizure, neuroprotective, and cognitive benefits. Its EEG, histopathology, and behavioral data support dual AMPA/NMDA receptor targeting as a strategy for limiting acute seizures and subsequent neurological injury, while remaining preclinical.

• GSK2606414 for PERK-Driven ER Stress Research

  2026-08-12

  GSK2606414 is a potent, selective PERK inhibitor for separating PERK-dependent signaling from broader unfolded protein response effects. This practical guide translates a TMAO-driven zebrafish NAFLD study into cell, tissue, and translational workflows with assay controls and troubleshooting strategies.

• Palmitic acid: Protocol and QC Guide

  2026-08-12

  Palmitic acid (SKU N2456) provides a characterized source of hexadecanoic acid for non-aqueous fatty-acid supplementation and research involving lipid metabolism, inflammation signaling, and protein palmitoylation. It is water-insoluble, should not be retained as a long-term solution, and requires solvent-matched controls and prompt use after reconstitution.

• Mianserin HCl: Clinical Efficacy and Plasma Levels

  2026-08-11

  The reference study provided an early integrated evaluation of mianserin hydrochloride by comparing antidepressant efficacy, adverse effects, and plasma concentrations with amitriptyline in depressed in-patients. Its main practical contribution was showing similar apparent therapeutic efficacy, fewer reported side effects, and no clear relationship between measured plasma mianserin and clinical improvement.

16627 records 1/1109 page Next 12345 下5页 Last page